Myungmoon Phar (017180) - Total Assets
Based on the latest financial reports, Myungmoon Phar (017180) holds total assets worth ₩270.19 Billion KRW (≈ $183.11 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 017180 total equity for net asset value and shareholders' equity analysis.
Myungmoon Phar - Total Assets Trend (2009–2024)
This chart illustrates how Myungmoon Phar's total assets have evolved over time, based on quarterly financial data.
Myungmoon Phar - Asset Composition Analysis
Current Asset Composition (December 2024)
Myungmoon Phar's total assets of ₩270.19 Billion consist of 31.1% current assets and 68.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.7% |
| Accounts Receivable | ₩38.09 Billion | 14.8% |
| Inventory | ₩32.68 Billion | 12.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩528.86 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Myungmoon Phar's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Myungmoon Phar worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Myungmoon Phar's current assets represent 31.1% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2024, down from 2.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 14.8% of total assets.
Myungmoon Phar Competitors by Total Assets
Key competitors of Myungmoon Phar based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Myungmoon Phar - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.97 | 0.84 | 0.64 |
| Quick Ratio | 0.58 | 0.49 | 0.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-2.44 Billion | ₩-14.62 Billion | ₩-44.74 Billion |
Myungmoon Phar - Advanced Valuation Insights
This section examines the relationship between Myungmoon Phar's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.1% |
| Total Assets | ₩257.99 Billion |
| Market Capitalization | $40.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Myungmoon Phar's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Myungmoon Phar's assets grew by 9.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Myungmoon Phar (2009–2024)
The table below shows the annual total assets of Myungmoon Phar from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩257.99 Billion ≈ $174.83 Million |
+9.06% |
| 2023-12-31 | ₩236.55 Billion ≈ $160.31 Million |
+2.65% |
| 2022-12-31 | ₩230.45 Billion ≈ $156.17 Million |
+3.49% |
| 2021-12-31 | ₩222.68 Billion ≈ $150.90 Million |
-8.37% |
| 2020-12-31 | ₩243.03 Billion ≈ $164.69 Million |
-8.10% |
| 2019-12-31 | ₩264.44 Billion ≈ $179.21 Million |
+8.79% |
| 2018-12-31 | ₩243.07 Billion ≈ $164.72 Million |
+3.40% |
| 2017-12-31 | ₩235.08 Billion ≈ $159.31 Million |
+6.33% |
| 2016-12-31 | ₩221.08 Billion ≈ $149.82 Million |
+10.86% |
| 2015-12-31 | ₩199.42 Billion ≈ $135.14 Million |
+4.59% |
| 2014-12-31 | ₩190.66 Billion ≈ $129.21 Million |
-0.91% |
| 2013-12-31 | ₩192.41 Billion ≈ $130.39 Million |
+2.16% |
| 2012-12-31 | ₩188.34 Billion ≈ $127.63 Million |
-7.00% |
| 2011-12-31 | ₩202.50 Billion ≈ $137.23 Million |
+23.36% |
| 2010-12-31 | ₩164.15 Billion ≈ $111.24 Million |
+6.70% |
| 2009-12-31 | ₩153.85 Billion ≈ $104.26 Million |
-- |
About Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more